• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Spark Therapeutics Appoints CTO

    Cryoport Launches ESG Program

    U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail

    Thermo Fisher Scientific Completes Mesa Biotech Acquisition

    Ashfield Engage, Popit Form Digital Monitoring Collaboration
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Solid Dose Market Trends

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    C2 Pharma Completes Multiple Regulatory Filings

    Bormioli Opens New Glass Research Center
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Ashfield Engage, Popit Form Digital Monitoring Collaboration

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    CrownBio & JSR Life Sciences Partner with Cambridge Quantum Computing
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    test company saurabh

    Baxter BioPharma Solutions

    Aphena Pharma Solutions

    Almac Group

    Adare Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Reed-Lane

    test company saurabh

    Almac Group

    Aphena Pharma Solutions

    Alcami
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Pharma Beat

    NSAIDs – Friend or Foe?

    Although widely used for years, NSAIDs have side effects that could eventually change their OTC status

    Related CONTENT
    • Know the Challenges of Biosimilar Manufacturing
    • Tapemark Passes Regulatory Hurdle
    • Warning Letters & Close-out Letters
    • BioPharma Services Completes 3 FDA Inspections
    • Frontida BioPharm Launches Expansion Efforts
    Adele Graham-King, Contributing Editor06.06.17
    Non-Steroidal Anti-inflammatory Drugs (NSAID’s) are a group of pharmacologically active agents widely used in the routine treatment of pain and inflammation. The oldest and probably widest known of these compounds is aspirin (salicylic acid), which has been available commercially and clinically since 1899 and was used extensively throughout the world up until the mid-20th Century. After that the arrival of acetaminophen in 1956 was closely followed by ibuprofen in 1962. Naproxen arrived in 1976, the last of the non-selective NSAIDs before the COX inhibitors at the end of the Century.

    Although widely used, aspirin has various well-documented side effects mostly gastro-intestinally related. And as generic versions of the drug became available, the arrival of acetaminophen resulted in aspirins dip in popularity due to a much improved side-effect profile and lack of GI disturbance offered by other options. This situation continued up until the mechanism of the action of aspirin was discovered by British pharmacologist John Vane and his work into the anti-clotting capabilities of aspirin came to light throughout 1960s to 1980s. It’s for these reasons that there was an absolute resurgence in the use of what was then considered as almost a wonder drug for prevention of strokes and heart attacks towards the end of the 20th century. At one point there was almost the suggestion of putting aspirin in drinking water in the same way as flouride to divert occlusive disease, and prevent strokes and heart attacks. Although this was banded around, it was never taken seriously. It is acknowledged that not everyone should take aspirin due to its anti-coagulative properties.

    More selective NSAID’s came to market in the early 21st Century and these cyclooxygenase (COX)-1 and COX-2 inhibitors demonstrate an improved side effect profile due to their selective nature. The specificity has allowed them to be used to treat different inflammatory diseases such as osteo-arthritis and rheumatoid arthritis. However, these newer compounds still work with the same mechanism as their earlier cousins.

    Aspirin has and does remain the main stay of treatment for secondary prevention of cardiovascular (CV) events and the FDA published updated guidance on this in 2014. The FDA states that “available evidence supports the use of aspirin for preventing another heart attack or stroke in patients who have already had a heart attack, or stroke, or have other evidence of coronary artery disease.” What they also state is that they do not support use in primary prevention and indeed that “there are serious risks associated with the use of aspirin, including increased risk of bleeding in the stomach and the brain.” As a result questions have arisen with regards to the safety of these widely used and available treatments.

    For a group of drugs that have been highly advocated as being protective, there is now mounting evidence that people who use high doses of the NSAIDs are actually at greater risk of having heart attacks and other cardiovascular issues. However, such evidence is hard to judge. The most recent study published in the British Medical Journal (BMJ) in May 2017 suggests that there is a direct link between the likes of aspirin and ibuprofen and these heart problems. In the observational study conducted and led by Michele Bally at the University of Montreal Hospital Research Centre 446,763 sets of patient data from Canada, Finland and the UK were analyzed in order to ascertain when heart issues may arise. The authors concluded that taking a NSAID could raise the risk of having a heart attack as early as a week after commencing treatment with the greatest risk being in the first 30 days. This risk is particularly defined if patients are taking high doses, such as over 1200mg ibuprofen a day. However, due to the demographics of the patient population, and the fact that the study was observational, no definitive causal link may be established.

    It has been pointed out that due to the fact that patients taking excessively high doses of the non-steroidal therapies are clearly in immense pain from either injury or disease, and having a heart attack a week following initiation of NSAID therapy could not necessarily be attributed to the drug. It is entirely feasible that a myodcardial infarct could be down to either a previously underlying condition of something entirely different.

    It is however food for thought that there could be a link and with 61,460 of the patients studied having suffered from a heart attack, the researchers reported an increased risk of 75% with both ibuprofen and naproxen. Furthermore in March 2017 a Danish study group based at the University of Copenhagen published evidence in the European Heart Journal concluding that in their patient cohort taking ibuprofen can increase the risk of MI by 31%.

    There has been previously established links between non-steroidals and heart failure whereby in 2016 research published in the BMJ by an Italian research group based at University of Milano-Biocca who presented data from 10 million patient cases from across the UK, Netherlands, Italy and Germany. They concluded that taking this group of medicines could increase the risk of hospitalization due to heart failure by 19%. UK findings suggested that this wasn’t particularly relevant for under-65s, however, the older population should well consider the implications.

    In fairness, the use of aspirin around cardiovascular events is reasonably well established and much research time has been invested into this area of study. In general it is also not the treatment of choice for pain relief these days. However, ibuprofen, and naproxen are available over-the-counter in the U.S. and probably sit in most peoples’ handbags or backpacks to relieve that hangover, headache or pulled muscle at the gym. Clearly these medicines have a place in the treatment pathways of many disease areas and are valuable clinical tools. However, as the authors of the BMJ article point out, it has to be worthwhile considering their use and aiming to obtain the lowest possible dose for pain management, for the least possible time. The mounting evidence on the relationship between non-steroids and cardiovascular events presents a tricky balancing act when it comes to their use. It leaves them swinging between friend and foe and we can only hope that more definitive guidance is established in the near future. In the interim there are shouts from researchers for tighter control of medicines and potentially considering returning some from OTC status back to P (pharmacy) status, or some even to Prescription Only Medicine (POM) in order to ensure guidance is supplied at the time of purchase. Some may consider this a step backwards but with growing evidence as to the implications of treatment it surely has the potential to be on the horizon.


    Adele Graham-King
    Contributing Editor

    Adele is a design consultant who works in product development for medical and healthcare applications. Her background is in pharma, and she has a degree in applied physiology.
    Related Searches
    • canada
    • fda
    • generic
    • events
    Suggested For You
    Know the Challenges of Biosimilar Manufacturing Know the Challenges of Biosimilar Manufacturing
    Tapemark Passes Regulatory Hurdle Tapemark Passes Regulatory Hurdle
    Warning Letters & Close-out Letters Warning Letters & Close-out Letters
    BioPharma Services Completes 3 FDA Inspections BioPharma Services Completes 3 FDA Inspections
    Frontida BioPharm Launches Expansion Efforts Frontida BioPharm Launches Expansion Efforts
    Tackling TB Resistance Tackling TB Resistance
    The FDA and Metrics The FDA and Metrics
    How Molded Tubing Manifold Assemblies Prevent Leaks How Molded Tubing Manifold Assemblies Prevent Leaks
    Could Nuts Ward Off Cancer? Could Nuts Ward Off Cancer?
    Generic Drug Trends Generic Drug Trends
    The Trials and Tribulations  of Male Contraception The Trials and Tribulations of Male Contraception
    LSNE Completes Two FDA Inspections LSNE Completes Two FDA Inspections
    3D Printing Meets Pharma: Reward & Risk 3D Printing Meets Pharma: Reward & Risk
    ‘Smart’ Heparin Delivery Could Self-Modulate ‘Smart’ Heparin Delivery Could Self-Modulate
    FDA’s Quality Agreements Guidance FDA’s Quality Agreements Guidance

    Related Pharma Beat

    • Drug Development | Drug Discovery
      Tackling TB Resistance

      Tackling TB Resistance

      The TB Alliance is partnering with universities, government agencies, public agencies and a small number of pharma compani
      Adele Graham-King, Contributing Editor 05.09.17

    • Drug Development

      Could Nuts Ward Off Cancer?

      Recent research looks into the anti-cancer properties of various nuts
      Adele Graham-King, Contributing Editor 04.03.17

    • Drug Delivery | Drug Development | R&D

      ‘Smart’ Heparin Delivery Could Self-Modulate

      A group of researchers have spent the past two years investigating self-controlling dosing and monitoring systems
      Adele Graham-King, Contributing Editor 01.26.17


    • Drug Development | Drug Discovery | R&D

      Is Nicotine Such a ‘Bad Boy’?

      Investigating this controversial compound’s potential health benefits
      Adele Graham-King, Contributing Editor 11.09.16

    • Drug Development | Drug Discovery | R&D

      Blackberry Wine: Could it Help Your Diabetes?

      Recent research points towards the positive impact ‘berry wine’ might have on diabetes
      Adele Graham-King, Contributing Editor 10.11.16

    • Chemistry | Drug Development
      Anyone Fancy a Beer?

      Anyone Fancy a Beer?

      The centuries-old brew continues to be investigated for its medicinal properties
      Adele Graham-King, Contributing Editor 05.05.16


    • Drug Development

      Chipping Away at the Old Cancer Block

      Advances in cancer treatment continue to march towards finding a cure
      Adele Graham-King, Contributing Editor 04.05.16

    • Clinical Trials | Drug Development

      The 3D Printed Pill

      It’s the future…or is it?
      Adele Graham-King, Contributing Editor 01.28.16

    • Clinical Trials | Drug Development | Drug Discovery | R&D

      Are We There Yet?

      Many promising cancer treatments are on the horizon
      Adele Graham-King, Contributing Editor 07.14.15


    • APIs | Bioassay Development | Drug Development | Methods Development | Process Development | Toxicology

      The Last Chance Saloon?

      Looking at the pharmaceutical ‘diet’ of anti-obesity drugs
      Adele Graham-King, Contributing Editor 06.02.15

    • Clinical Trials | Drug Development

      100 New Drugs in 10 Years?

      Repurposing drug candidates that never saw the light of day
      Adele Graham-King, Contributing Editor 03.06.15

    • APIs | Bioassay Development | Clinical Trials | Drug Development | Drug Discovery | Methods Development | Process Development | R&D | Toxicology

      Experimental Drugs

      To use or not to use unlicensed drugs? That is the question.
      Adele Graham-King, Contributing Editor 01.29.15


    • Drug Delivery | Drug Development
      The End of a Century

      The End of a Century

      Looking at 15 years of pharmaceutical evolution.
      Adele Graham-King 10.14.14

    • Bioassay Development | Drug Development | Methods Development | Process Development | Toxicology

      A Questionable Combination

      ...
      Ed Silverman, Contributing Editor 06.05.13

    • Drug Development | R&D

      The Long Pharm of the Law

      Will FDA pursue criminal charges for execs in pharma cases?
      Ed Silverman 04.05.10

    Trending
    • Spark Therapeutics Appoints CTO
    • Inside A Vaccine Trial
    • Catalent Acquires Delphi Genetics
    • Wavelength Pharmaceuticals Acquires Majority Stake In Vanamali Organics
    • Pfizer Selects Seven Bridges To Support RNA Sequencing Data
    Breaking News
    • Spark Therapeutics Appoints CTO
    • Cryoport Launches ESG Program
    • U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail
    • Thermo Fisher Scientific Completes Mesa Biotech Acquisition
    • Ashfield Engage, Popit Form Digital Monitoring Collaboration
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Preliminary Study Links Markers of Impaired Bone Health to Vegan Diet
    Refined Grains Linked to Heart Attack Risk, Early Death
    Kappa Bioscience Extends Research Partnership For COVID-19 Research
    Coatings World

    Latest Breaking News From Coatings World

    Nippon Paint Marine Wins Korea Export Award
    Universal Display Corporation, PPG Expand Global Production of UniversalPHOLED Materials
    PPG Introduces Premium Iso-free Primer Surfacer, Catalyst
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    January AI Raises $8.8 Million in New Funding
    FDA Clears Ava Fertility Tracking Wearable Device
    First Patient in Europe Treated With Diamondback 360 Coronary Orbital Atherectomy System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Spark Therapeutics Appoints CTO
    Cryoport Launches ESG Program
    U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    The Top Beauty Products of 2021, According to HelloGiggles
    Estée Lauder Taps Ana de Armas as Global Brand Ambassador
    Sephora Announces Significant Expansion
    Happi

    Latest Breaking News From Happi

    What You're Reading on Happi.com
    Cosmetic Chemical Sales To Post CAGR 5.8% To 2025
    ACI Urges Senate to Approve Regan as EPA Administrator
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Marshall & Bruce Adds Koenig & Bauer Rapida 106 41-Inch Seven-Color Press
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    FTA converts Forum & INFOFLEX to virtual events
    Xeikon launches two new digital label printing presses
    UFlex adds capacity in packaging films
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Texas Medical Technology Partners with My Protect Kit
    Mexico City Single-Use Plastics Ban Leads to Tampon Shortage
    Believe Diapers Launch in U.S.
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Fusion Robotics Receives FDA Clearance for Spinal Navigation and Robotics System
    Kaia Health Unveils Next-Gen Complete MSK Care Solutions
    First Implantation of CTL Amedica's Minimally Invasive Flex Tower
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login